Clinical Trial Update: Effects of ROFLUMILAST on Subclinical Atherosclerosis in Chronic Obstructive Pulmonary Disease (COPD) [Phase 4]

View source ↗

Summary

Phase 4 trial assessing the effects of roflumilast on subclinical atherosclerosis in COPD; study completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Roflumilast (roflumilast)

Snippet

Sponsor: LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology | Conditions: Chronic Obstructive Pulmonary Disease and Allied Conditions | Phase 4 | Status: COMPLETED | Results posted: 2019-04-12